Skip to main content Accessibility help
  • Print publication year: 2012
  • Online publication date: July 2012

Chapter 6 - CNS drug development – Phase III


Akil, H., Brenner, S., Kandel, E., et al. (2010). The future of psychiatric research: genomes and neural circuits. Science, 327, 1580–81.
Arrowsmith, J. (2011). Trial watch: Phase III and submission failures: 2007–2010. Nat Revs Drug Discov, 10, 87.
Colagiuri, B. (2010). Participant expectancies in double blind randomized placebo controlled trials: potential limitations to trial validity. Clinic Trials, 1–10.
DeMuro, C., Clark, M., Mordin, M., et al. (2011). Reasons for rejection of PRO label claims: an analysis based on a review of PRO use among new molecular entities and biologic license applications 2006–2010. Poster at ISPOR 16th Annual International Meeting, May 21–25, Hilton Baltimore, Baltimore, MD, USA.
EMEA, C.F.M.P.F.H.U.C. reflection paper on the regulatory guidance for the use of health related quality of life (HRQL) measures in the evaluation of medicinal products. 16 March 2010.
FDA Guidance for Industry End-of-Phase IIa Meetings. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), September 2009.
Guidance for Industry Suicidality: Prospective Assessment of Occurrence in Clinical Trials. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), September 2010.
Hammad, T. A., Laughren, T., and Racoosin, J. (2006). Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatr, 63, 332–339.
International Conference on Harmonization (ICH) of Technical Requirements for Regulations of Pharmaceuticals for Human use. ICH Tripartite Guideline E-9 Document, Statistical Principles for Clinical trials, 5 February 1998.
Kemp, A. S., Schooler, N. R., Kalali, A. H., et al. (2010). What is causing the reduced drug–placebo difference in recent schizophrenia clinical trials and what can be done about it?Schizophrenia Bull, 36, 504–9.
Kinon, B. J., Potts, A. J., and Watson, S. B. (2011). Placebo response in clinical trials with schizophrenia patients. Curr Opin Psychiat, 24, 107–13.
Kola, I. and Landis, J. (2004). Nat Rev Drug Discov, 3, 711–15.
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., et al. (2010). How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov, 9, 203–14.
Rush, A. J., Trivedi, M. H., Wisniewski, S. R. (2006a). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D Report. Am J Psychiat, 163, 1905–17.
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., et al. (2006b). STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New Engl J Med, 354, 1231–42.
Stone, M., Laughren, T., Jones, M. L., et al. (2009). Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration, Brit Med J, 339, 2880.
Targum, S., Pollack, M., and Fava, M. (2008). Redefining affective disorders: relevance for drug development. CNS Neurosci Therapeut, 14, 2–9.
Walsh, B. T., Seidman, S. N., Sysko, R., and Gould, M. (2002). Placebo response in studies of major depression: variable, substantial, and growing. J Am Med Assoc, 287, 1840–47.
Wisniewski, S. R., Rush, A. J., Nierenberg, A. A., et al. (2009). Can Phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D Report. Am J Psychiat, 166, 599–607.